The short version of Semax fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
==== Phosphodiesterase PDE5 inhibitors ==== Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [114] Lodenafil (CRIS-031; Helleva) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [115] Mirodenafil (Aibishi; Bravonto; Mvix; SK-3530) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [116] Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [117] Sildenafil chewable tablets (Nurigra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [118] Sildenafil orally soluble film (sildenafil ODF; SPO-1101; Vultis) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [119] Sildenafil orally soluble film (orodispersible sildenafil; Please; sildenafil oral dissolving film; sildenafil orally-disintegrating film; sildenafil OSF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [120] Sildenafil oral spray (ASP-001; ASP-002; Bandol; Hezkue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [121] Sildenafil oro-dispersible tablets (Erecta; FACSID-50) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [122] Simmerafil (Onvita; Onweida; semenafil; TPN-171; TPN-171-H) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [123] Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [124] Tadalafil oral disintegrating film (SPO-1102; Vulteum; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [125] Tadalafil oral film (OGOOD) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [126] Udenafil (DA-8159; Jurvigo; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [127] Vardenafil (BAY-389456; Levitra; Nuviva; Staxyn; vardenafil ODT; vardenafil orodispersible tablet; Vivanza) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [128]
=== Indian Farmers Fertiliser Cooperative (IFFCO) === Indian Farmers Fertiliser Cooperative Limited (IFFCO) was registered on November 3, 1967, as a Multi-Unit Co-operative Society. On the enactment of the Multistate Co-operative Societies Act 2002, the Society is deemed to be registered as a Multistate Co-operative Society. The Society is primarily engaged in production and distribution of fertilisers. The byelaws of the Society provide a board frame work for the activities of IFFCO as a Co-operative Society. At IFFCO, the thirst for ever improving the services to farmers and member cooperatives is insatiable, commitment to quality is isurmountable and harnessing of mother earths' bounty to drive hunger away from India in an ecologically sustainable manner is the prime mission. See also:
Primary food processing turns agricultural products, such as raw wheat kernels or livestock, into something that can eventually be eaten. This category includes ingredients that are produced by ancient processes such as drying, threshing, winnowing and milling grain, shelling nuts, and butchering animals for meat. It also includes deboning, cutting, freezing and smoking of animal products, extracting and filtering oils, canning food, preserving food through food irradiation, and candling eggs, as well as homogenizing and pasteurizing milk. Contamination and spoilage problems in primary food processing can lead to significant public health threats, as the resulting foods are used so widely. However, many forms of processing contribute to improved food safety and longer shelf life before the food spoils. Commercial food processing uses control systems such as hazard analysis and critical control points (HACCP) and failure mode and effects analysis (FMEA) to reduce the risk of harm.
=== Bioactivation of antitumor agents === Several anti-tumor agents such as mitosenes, indolequinones, aziridinylbenzoquinones and β-lapachone have been designed be bioactivated by NQO1 from various prodrugs. The high levels of NQO1 expression in many human solid tumors compared to normal tissue ensures their selective activation within tumor cells.
Sources: en.wikipedia.org
== Selected publications == Brodbelt, Jennifer S. (24 March 2014). "Photodissociation mass spectrometry: new tools for characterization of biological molecules". Chemical Society Reviews. 43 (8): 2757–2783. doi:10.1039/C3CS60444F. ISSN 1460-4744. PMC 3966968. PMID 24481009. Shaw, Jared B.; Li, Wenzong; Holden, Dustin D.; Zhang, Yan; Griep-Raming, Jens; Fellers, Ryan T.; Early, Bryan P.; Thomas, Paul M.; Kelleher, Neil L.; Brodbelt, Jennifer S. (28 August 2013). "Complete Protein Characterization Using Top-Down Mass Spectrometry and Ultraviolet Photodissociation". Journal of the American Chemical Society. 135 (34): 12646–12651. Bibcode:2013JAChS.13512646S. doi:10.1021/ja4029654. PMC 3757099. PMID 23697802. Kempen, Esther C.; Brodbelt, Jennifer S. (1 November 2000). "A Method for the Determination of Binding Constants by Electrospray Ionization Mass Spectrometry". Analytical Chemistry. 72 (21): 5411–5416. doi:10.1021/ac000540e. ISSN 0003-2700. PMID 11080894.
Half-Life was followed by an expansion pack, Opposing Force, on November 1, 1999, developed by Gearbox Software. Players control US Marine corporal Adrian Shephard, who fights a new group of aliens and black operations units. Opposing Force was received favorably by critics, many citing the game as being as influential on setting expansion pack standards as the original game had been in influencing the overall genre. The game won the Computer Game of the Year Interactive Achievement Award of 2000 from the Academy of Interactive Arts & Sciences.
==== Fat ==== Based on the findings that FNDC5 induces thermogenin expression in fat cells, overexpression of FNDC5 in the liver of mice prevents diet-induced weight gain, and FNDC5 mRNA levels are elevated in human muscle samples after exercise, it has been proposed that irisin promotes the conversion of white fat to brown fat in humans, which would make it a health-promoting hormone. While this proposal has been challenged by evidence finding FNDC5 is upregulated only in highly active elderly humans, more recent literature has supported the hypothesis of FNDC5 and irisin having a necessary role in exercise related benefits.
Sources: en.wikipedia.org
In traditional amphetamine pharmacology, TAAR1 activation triggers intracellular phosphorylation signaling cascades that facilitate and optimize the structural reversal of monoamine transporters (MATs) to allow efficient neurotransmitter efflux. Because cathinones fail to activate TAAR1, this phosphorylation is absent, rendering carrier-mediated efflux less efficient. Consequently, displaced neurotransmitters tend to accumulate and linger within the cytoplasm rather than being cleanly exported to the synaptic cleft, promoting intracellular auto-oxidation, and faster depletion. Psychostimulants differ in their relative affinity for DAT, SERT and NET. In a study done on brain cells of male rats 3-CMC was found to interact on a relatively similar level with DAT and NET as mephedrone, while it interacts significantly less with SERT. Another study done on male rats also concludes that 3-CMC causes more release of dopamine in proportion to serotonin whereas mephedrone releases relatively more serotonin. 3-CMC produces hyperlocomotion, a psychostimulant-like effect, in rodents. It substitutes for cocaine in drug discrimination tests in monkeys. The drug is less potent in substituting for cocaine than methcathinone, which has been theorized to be due to its greater capacity to induce serotonin release and to thereby inhibit its own reinforcing effects.
Other attempts to extend ceramic petrography include the use of automated image analysis, the palaeontological analysis of microscopic fossils within ceramic thin sections and the combined statistical classification of petrographic and chemical data from artefacts. Examples of Ceramic Petrography in archaeological settlements:
== Chemistry == The experimental log P of penbutolol is 4.15. Penbutolol showed the second highest predicted lipophilicity of 30 clinically relevant beta blockers, with the most lipophilic beta blocker predicted to be the lesser-known bopindolol.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.